Precision gene delivery remains one of the greatest challenges in modern medicine. A Basel-based biopharma company, Vector BioPharma, has accepted the challenge and, with cutting-edge technology from the University of Zürich, is developing a revolutionary new way to deliver the right genes to the right place at the right time. Vector BioPharma aims to be the pioneer in delivering future medicines with this technology, now under development in multiple areas of urgent medical need.

As a late-stage investor focusing on the European bioeconomy, the ECBF is carefully assessing the maturity of any technology, but more important than maturity is the ability to reach commercial scale. What governs that scale-up, and how do we assess it? What role does the TRL score play, and what key questions do we ask? An excerpt into a framework.

BioFIT is Europe’s leading partnering event in Life Sciences for tech transfer, early-stage innovation deals and pre-seed, seed and Series A investment, receiving each year more than 1,000 delegates from over 35 countries. For its 11th edition, BioFIT will be held in Strasbourg, France on November 29th and 30th, and on a digital format on December 7th and 8th.

Takeda, Boehringer Ingelheim and Novartis do it repeatedly. Global players make ­major investments in their Austrian facilities. Not only multinationals but start-ups and scale-ups such as ­Apeiron Biologics and ViraTherapeutics benefit from a comprehensive ecosystem – from basic research to production and distribution. The business location agency ABA is the first point of contact for setting up operations in Austria.